Alpha Cognition (ACOG) – Research Analysts’ Weekly Ratings Changes

Alpha Cognition (NASDAQ: ACOG) recently received a number of ratings updates from brokerages and research firms:

• 8/20/2026 – Alpha Cognition is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $21.00 price target on the stock.
• 8/19/2026 – Alpha Cognition is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $21.00 price target on the stock.
• 8/17/2026 – Alpha Cognition had its price target raised by HC Wainwright from $18.00 to $20.00. They now have a “buy” rating on the stock.
• 8/15/2026 – Alpha Cognition was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/14/2026 – Alpha Cognition had its “buy” rating reaffirmed by Craig Hallum. They now have a $17.00 price target on the stock.
• 7/10/2026 – Alpha Cognition is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $20.00 price target on the stock.
• 7/10/2026 – Alpha Cognition is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $20.00 price target on the stock.

Insiders Place Their Bets

In other news, Director Robert Wills acquired 10,000 shares of Alpha Cognition stock in a transaction dated Friday, August 21st. The shares were acquired at an average cost of $9.62 per share, for a total transaction of $96,200.00. Following the acquisition, the director owned 32,241 shares of the company’s stock, valued at $310,158.42. This trade represents a 44.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.60% of the stock is currently owned by company insiders.

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.